N+1 Singer Increases Horizon Discovery Group PLC (HZD) Price Target to GBX 250
Horizon Discovery Group PLC (LON:HZD) had its price target boosted by analysts at N+1 Singer from GBX 219 ($2.95) to GBX 250 ($3.37) in a report released on Friday. The firm presently has a “buy” rating on the stock. N+1 Singer’s price objective points to a potential upside of 5.04% from the stock’s current price.
HZD has been the subject of a number of other reports. Shore Capital reissued a “not rated” rating on shares of Horizon Discovery Group PLC in a research note on Wednesday, July 19th. Numis Securities Ltd reissued a “buy” rating and set a GBX 300 ($4.04) price objective on shares of Horizon Discovery Group PLC in a research note on Thursday. Beaufort Securities restated a “speculative buy” rating and set a GBX 200 ($2.70) target price on shares of Horizon Discovery Group PLC in a research report on Wednesday, May 31st. Finally, Royal Bank Of Canada raised their target price on shares of Horizon Discovery Group PLC from GBX 220 ($2.97) to GBX 245 ($3.30) and gave the stock a “speculative buy” rating in a research report on Thursday, July 20th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of GBX 240 ($3.24).
Horizon Discovery Group PLC (LON HZD) opened at 238.00 on Friday. The company has a 50-day moving average price of GBX 252.40 and a 200-day moving average price of GBX 213.69. Horizon Discovery Group PLC has a 12-month low of GBX 104.00 and a 12-month high of GBX 289.00. The firm’s market capitalization is GBX 226.68 million.
Horizon Discovery Group PLC Company Profile
Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.